Answers are grounded in this paper and cite their sources.
Intranasal administration of heat-inactivated Bifidobacterium longum CCM7952 (Bl7952) alleviates allergic airway inflammation (AAI); however, the specific cell-wall components responsible for this anti-allergic effect, as well as the underlying immunological mechanism, remain unknown. In this study, the anti-allergic and immunomodulatory properties of Bl7952 cell-wall components were investigated in female BALB/c, C57BL/6, NOD2 −/− , and MyD88 −/− mice using a murine model of AAI. Four hours before each allergen (ovalbumin) application, isolated Bl7952 surface components, including slime and cell wall-derived polysaccharides, surface proteins, or a peptidoglycan preparation, were administered intranasally. Among these components, only the peptidoglycan preparation significantly down-regulated the Th2-associated immune response and eosinophil infiltration into the lungs. This effect was largely dependent on MyD88 adapter protein and independent of NOD2 receptor signaling. Furthermore, the Bl7952-derived peptidoglycan preparation altered the frequencies of antigen-presenting and T cells in the lungs of naïve mice. Thus, the peptidoglycan preparation from Bl7952 exerts prophylactic anti-allergic effects, underscoring its potential as an immunomodulator for preventing AAI.
No takes yet. Share an insight, caveat, or question.
Horníková et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: